A revolutionary breakthrough in medical science could mean the beginning of the end for one of the deadliest diseases affecting women: breast cancer.

In a major leap forward, researchers from Anixa Biosciences and the Cleveland Clinic announced the successful completion of phase one clinical trials for a breast cancer vaccine that showed a strong immune response in over 75% of participants. The study marks what could be a defining moment in the global fight against cancer.

“This is very exciting,” said Dr. Amit Kumar, CEO of Anixa Biosciences. “If this works and is able to prevent cancer, then we can perhaps eliminate breast cancer as a disease, just like we’ve done with polio and other infectious diseases.”

The trial included 35 women, most of whom had been previously diagnosed with triple-negative breast cancer—one of the most aggressive and difficult-to-treat forms. This is the same type of cancer that led actress Angelina Jolie to undergo a preventative double mastectomy after discovering she carried the BRCA1 gene mutation.

Each participant received the vaccine and had their blood periodically analyzed to measure the presence of antibodies on T and B cells, which are essential parts of the body’s immune response. The goal was to determine whether the immune system could be trained to recognize and attack cancer cells before tumors even formed.

The early results were overwhelmingly positive: more than three-quarters of the women developed a robust immune response with no significant side effects, except minor irritation at the injection site.

A New Kind of Cancer Vaccine

Unlike traditional vaccines that target viruses or bacteria, this vaccine targets something much trickier: cancerous cells that originate from the body’s own tissue. That has historically made cancer vaccines hard to develop, as the immune system typically doesn’t recognize cancer cells as threats.

“Cancer arises from your own healthy cells,” Kumar explained. “So the immune system is not able to see very distinctly that the cancer cell is a bad cell.”

This particular vaccine focuses on a protein called alpha-lactalbumin, which is only naturally present in a woman’s body during pregnancy and lactation. By targeting a molecule that is otherwise dormant, the vaccine can distinguish cancer cells from normal ones—without the risk of attacking healthy organs.

The idea came from a Cleveland Clinic scientist in 2018, who proposed vaccinating women no longer planning to have children, thereby eliminating the risk of disrupting lactation while taking advantage of the protein’s limited natural presence.

Backed by the Department of Defense

The research has been funded by the U.S. Department of Defense, recognizing both the national health impact and the innovative science behind the vaccine. However, Kumar expressed concern that ongoing federal budget cuts might jeopardize future trials.

“There’s a lot of uncertainty,” he admitted. Still, the research team plans to present their findings to the White House later this year in hopes of securing broader support.

Phase two of the clinical trial is expected to launch next year and will include a larger participant group. The vaccine will also be tested against other types of breast cancer.

A Global Impact Within Reach

One in eight women will develop breast cancer in their lifetime, making it the most common cancer in the world. If future trials continue to show such promising results, the vaccine could drastically reduce both incidence and mortality rates—and potentially eradicate the disease altogether by 2030.

The scientific community has long hoped for a viable cancer vaccine. While cancer treatment has made enormous strides through surgery, radiation, chemotherapy, and immunotherapy, prevention remains the holy grail.

“This could be the first true cancer vaccine that works,” Kumar said. “It’s the culmination of years of work—and it could change everything.”

If all goes according to plan, what began in a lab at the Cleveland Clinic may soon be saving lives around the globe.